^
1d
Spatial transcriptomics uncovers unique tumor microenvironments in folliculotropic versus classic mycosis fungoides. (PubMed, J Invest Dermatol)
These findings suggest the follicular microenvironment may provide survival advantages to malignant T cells while promoting a dysregulated anti-tumor immune response. These observations provide insight into the mechanisms underlying the more aggressive clinical features of FMF versus CMF.
Journal
|
CD4 (CD4 Molecule) • IL2 (Interleukin 2)
3d
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL (clinicaltrials.gov)
P1/2, N=38, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Aug 2038 --> Nov 2039 | Trial primary completion date: Sep 2027 --> Dec 2025
Enrollment closed • Trial completion date • Trial primary completion date
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 expression
|
TT11
4d
Early-Onset Hypopigmented Mycosis Fungoides in a Young Female: Navigating Diagnostic Delays and Treatment Complexities-A Case Report. (PubMed, Clin Case Rep)
However, the patient relapsed within a few months and needed to be treated with methotrexate. This example highlights the importance of careful clinical, histological, and immunohistochemical testing for timely HMF detection as well as the need for vigilant monitoring to effectively manage recurrences.
Journal
|
CD4 (CD4 Molecule)
|
methotrexate
5d
Tumoral Stage of Mycosis Fungoides, Misdiagnosed With Wells Syndrome and Langerhans Cell Histiocytosis Histologically: A Challenging Case and Review of the Literature. (PubMed, Cancer Rep (Hoboken))
This case highlights the importance of considering MF in patients presenting with tissue eosinophilia or Langerhans cell infiltration, even when initial biopsies lack definitive features.
Review • Journal
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
8d
CDK9 is a dependency in GATA-3 driven and MCL-1 independent T-cell Lymphomas. (PubMed, Blood Cancer J)
We also identify novel mechanisms by which GATA-3 and CDK9 regulate rRNA transcription and processing, respectively, collaboratively promoting ribosome biogenesis. Therefore, CDK9 is a therapeutic vulnerability across genetically and transcriptionally diverse T-cell lymphomas, including those for which GATA-3 is oncogenic.
Journal
|
MCL1 (Myeloid cell leukemia 1) • CDK9 (Cyclin Dependent Kinase 9) • GATA3 (GATA binding protein 3)
9d
C-MYC expression analysis by immunohistochemistry in cases of subcutaneous panniculitis T-cell lymphoma and lupus panniculitis. (PubMed, Indian J Dermatol Venereol Leprol)
Conclusion This study highlights the importance of the IHC of c-MYC in diagnosing SPTCL vs. LP. The higher percentage of c-MYC-positive atypical cells in SPTCL suggests that this oncoprotein may have a significant involvement in the pathogenesis of SPTCL.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
9d
JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders. (PubMed, JAMA Dermatol)
This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations.
Journal • Tumor mutational burden
|
TMB (Tumor Mutational Burden) • JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • PCM1 (Pericentriolar Material 1) • CAPRIN1 (Cell Cycle Associated Protein 1)
|
TNFRSF8 positive
15d
New trial
|
B2M (Beta-2-microglobulin)
18d
Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report. (PubMed, Cureus)
This case highlights bexarotene as a promising therapeutic option for refractory pcALCL. Our experience reinforces the potential of bexarotene as a viable treatment for pcALCL, particularly in recurrent or refractory cases where conventional therapies are contraindicated or ineffective.
Journal
|
TNFRSF8 (TNF Receptor Superfamily Member 8)
|
TNFRSF8 positive
|
Targretin oral (bexarotene oral)
19d
OX-40 signaling promotes tumorigenesis in CTCL by regulating ERK activation. (PubMed, Front Immunol)
Therefore, the in vivo chick embryo metastasis model may serve as a valuable preclinical tool for identifying novel anti-tumor targets in CTCL. The OX-40 axis was identified as a key driver of CTCL progression, promoting tumor growth and metastasis through ERK activation while validating the chick embryo model as a preclinical tool for therapeutic testing.
Journal • IO biomarker
|
VEGFC (Vascular Endothelial Growth Factor C) • TNFRSF4 (TNF Receptor Superfamily Member 4) • TNFSF4 (TNF Superfamily Member 4)